FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average bu	ırden hours					
ner resnonse	0.5					

Check this box if no longer subject to Section 16. Form 4 or

Form 5 obligations may STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A Francis	ddress of Reporting Richard	Person D.	Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Ltd. [TEVA]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
	(First) narmaceutical In lanevi'a Street	(Middle) ndustries Ltd.	3. Date of Earliest Transaction (Month/Day/Year) 02/15/2023	X Officer (give title below) Other (specify below) President and CEO				
(Street) Tel Aviv L3 6944020 (City) (State) (Zip)			4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Transaction	2A. Deemed	3. Transaction		4. Securities Acquired			5. Amount of Securities Beneficially	6.	7. Nature of
(Instr. 3)	Date	Execution Date, if	Code		(A) or Disposed of (D)		of (D)	Owned Following Reported	Ownership	Indirect
	(Month/Day/Year)	any	(Instr. 8)		(Instr. 3, 4 and 5)			Transaction(s)	Form:	Beneficial
		(Month/Day/Year)		, ,				(Instr. 3 and 4)	Direct (D)	Ownership
									or Indirect	(Instr. 4)
						(A) or			(I)	
			Code	V	Amount	(D)	Price		(Instr. 4)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code	ion	5. Number Derivative Securities Acquired (A Disposed of (D) (Instr. 3, 4, 5)	A) or of	Expiration Date (Month/Day/Year) or		, ,		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following	Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	٧	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Restricted Share Units	(1)	02/15/2023		Α		484,966		(2)	(2)	Ordinary Shares (3)	484,966	\$ 0	484,966	D	

Explanation of Responses:

- (1) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- (2) Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.
- (3) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis	02/17/2023
**Signature of Reporting Person	Date

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} If the form is filed by more than one reporting person, see Instruction 4(b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.